1. Home
  2. Labeler Index
  3. Genentech, Inc.
  4. 50242-245
  5. NDC Package Code: 50242-245-01 Phesgo

NDC Package 50242-245-01 Phesgo

Pertuzumab,Trastuzumab,And Hyaluronidase-zzxf Injection, Solution Subcutaneous - View Billable Units, 11-Digit Format, RxNorm

Table of Contents

    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Other Packages
    4. Frequently Asked Questions

Package Information

Find all the important details about this NDC Package code, including the 11-Digit NDC Billing number, billing units, wholesale price, RxNorm crosswalk, active ingredients, pharmacologic clasess, etc.

NDC Package Code:
50242-245-01
Package Description:
1 VIAL, SINGLE-DOSE in 1 CARTON / 15 mL in 1 VIAL, SINGLE-DOSE
Product Code:
50242-245
Proprietary Name:
Phesgo
Non-Proprietary Name:
Pertuzumab, Trastuzumab, And Hyaluronidase-zzxf
Substance Name:
Hyaluronidase (human Recombinant); Pertuzumab; Trastuzumab
Usage Information:
PHESGO is contraindicated in patients with known hypersensitivity to pertuzumab, or trastuzumab, or hyaluronidase, or to any of its excipients.
11-Digit NDC Billing Format:
50242024501
Billing Unit:
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
NDC to RxNorm Crosswalk:
  • RxCUI: 2382604 - pertuzumab-trastuzumab-hyaluronidase-zzxf 1,200 MG / 600 MG / 30,000 UNT in 15 mL Injection
  • RxCUI: 2382604 - 15 ML hyaluronidase-zzxf 2000 UNT/ML / pertuzumab-zzxf 80 MG/ML / trastuzumab-zzxf 40 MG/ML Injection
  • RxCUI: 2382604 - pertuzumab-trastuzumab-hyaluronidase-zzxf 1,200 MG / 600 MG / 30,000 UNT per 15 ML Injection
  • RxCUI: 2382609 - PHESGO 1,200 MG / 600 MG / 30,000 UNT in 15 ML Injection
  • RxCUI: 2382609 - 15 ML hyaluronidase-zzxf 2000 UNT/ML / pertuzumab-zzxf 80 MG/ML / trastuzumab-zzxf 40 MG/ML Injection [Phesgo]
    • Product Type:
    Human Prescription Drug
    Labeler Name:
    Genentech, Inc.
    Dosage Form:
    Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
    Administration Route(s):
  • Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
    • Active Ingredient(s):
  • HYALURONIDASE (HUMAN RECOMBINANT) 30000 U/15mL
  • PERTUZUMAB 1200 mg/15mL
  • TRASTUZUMAB 600 mg/15mL
    • Pharmacologic Class(es):
  • Endoglycosidase - [EPC] (Established Pharmacologic Class)
  • Glycoside Hydrolases - [CS]
  • HER2/Neu/cerbB2 Antagonists - [MoA] (Mechanism of Action)
  • HER2/neu Receptor Antagonist - [EPC] (Established Pharmacologic Class)
    • Sample Package:
    No
    FDA Application Number:
    BLA761170
    Marketing Category:
    BLA - A product marketed under an approved Biologic License Application.
    Start Marketing Date:
    06-29-2020
    Listing Expiration Date:
    12-31-2024
    Exclude Flag:
    N
    Code Structure:

    The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

    * Please review the disclaimer below.

    NDC HCPCS Crosswalk

    This crosswalk is intended to help the public understand which drug products (identified by NDCs) are assigned to which HCPCS billing codes.

    NDC 50242-245-01 HCPCS crosswalk information with package details and bill units information.

    NDC Billing CodeHCPCS CodeHCPCS Code Desc.DosagePackage SizePackage QuantityBillable UnitsBillable Units / Pkg
    50242024501J9316Pertuzu, trastuzu, 10 mg10 MG151180180

    * Please review the disclaimer below.

    Other Product Packages

    The following packages are also available for this product:

    NDC Package CodePackage Description
    50242-245-861 VIAL, SINGLE-DOSE in 1 CARTON / 15 mL in 1 VIAL, SINGLE-DOSE

    * Please review the disclaimer below.

    Frequently Asked Questions

    What is NDC 50242-245-01?

    The NDC Packaged Code 50242-245-01 is assigned to a package of 1 vial, single-dose in 1 carton / 15 ml in 1 vial, single-dose of Phesgo, a human prescription drug labeled by Genentech, Inc.. The product's dosage form is injection, solution and is administered via subcutaneous form.

    Is NDC 50242-245 included in the NDC Directory?

    Yes, Phesgo with product code 50242-245 is active and included in the NDC Directory. The product was first marketed by Genentech, Inc. on June 29, 2020 and its listing in the NDC Directory is set to expire on December 31, 2024 if the product is not updated or renewed by the manufacturer.

    What is the NDC billing unit for package 50242-245-01?

    The contents of this package are billed per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.

    What is the 11-digit format for NDC 50242-245-01?

    The 11-digit format is 50242024501. The 11-digit billing format might be required by the Centers for Medicare & Medicaid Services (CMS) and other payers in billing claim forms.

    This package code is originally configured in a 5-3-2 segment 10-digit format and by adding a zero within the original NDC package code we can obtain the converted 11-digit format in a 5-4-2 segment configuration. The table below shows the 11-digit code conversion:

    10-Digit Format10-Digit Original Code11-Digit Format11-Digit Code
    5-3-250242-245-015-4-250242-0245-01